Clinical trials: Locally Advanced Colorectal Cancer
Colorectal Cancer
ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or…
- Trial name
- NCT00004193
- Testing
- ISIS 2503
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer
*As of June 2026- Phase I has been completed and we are now in Phase II. This phase I/II trial studies the side effects and how well fluorescence image guided surgery followed by intraoperative photodynamic therapy for improving…
- Conditions
- Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
- Trial name
- NCT06307548
- Testing
- Aminolevulinic Acid, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00007826
- Testing
- BCG vaccine, monoclonal antibody 105AD7 anti-idiotype vaccine, alum adjuvant
- Where
- United Kingdom
- Sponsor
- Onyvax
Colorectal Cancer
IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
The main purpose of this study is to assess the efficacy and safety of IBI310 in combination with sintilimab in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) locally advance or…
- Trial name
- NCT04258111
- Testing
- IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody)
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Colon Cancer
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer
A. Background and purpose: Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for unresectable locally advanced colon cancer: an open, multi-centered, randomize controlled phase 3 trial.
- Trial name
- NCT03970694
- Testing
- Radiotherapy, oxaliplatin+capecitabine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Advanced Cancer
Complete Versus Partial Preservation of Denonvilliers' Fascia on Urogenital Function in Locally Advanced Rectal Cancer
Total mesorectal resection (TME) is the standard surgical method for locally advanced rectal cancer, which significantly reduces the local recurrence rate. However, the incidence of urogenital dysfunction is higher.
- Trial name
- NCT04672603
- Testing
- Complete Preservation of Denonvilliers' Fascia
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Safety and Efficacy
Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
In this phase I single-arm clinical study, 20 patients with T4 unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4…
- Trial name
- UNLACC (NCT06244537)
- Testing
- MR-linac
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Rectal Neoplasms
Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
Locally advanced rectal cancer (T3, T4 or lymph node positive tumors) are conventionally treated with 5FU / capecitabine based chemoradiation prior to surgical resection.
- Trial name
- NCT02137356
- Testing
- standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Sheba Medical Center
Organ Preservation, Rectal Cancer
Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision
The goal of this prospective phase II feasibility study is to evaluate two additional local treatment options in rectal cancer patients with a good clinical response after neoadjuvant (chemo)radiation: contact x-ray brachytherapy…
- Conditions
- Organ Preservation, Rectal Cancer, Quality of Life, Locally Advanced Rectal Carcinoma
- Trial name
- OPAXX (NCT05772923)
- Testing
- Contact x-ray brachytherapy, Local excision
- Where
- 7 sites in Netherlands
- Volunteers
- 168 people
- Sponsor
- The Netherlands Cancer Institute
Rectal Cancer
RadioPathomics Artificial Intelligence Model to Predict Tumor Regression Grading in Locally Advanced Rectal Cancer
In this study, investigators apply a radiopathomics artificial intelligence (AI) supportive model to predict neoadjuvant chemoradiotherapy (nCRT) response before the nCRT is delivered for the patients with locally advanced rectal…
- Trial name
- RPAI-TRG (NCT04273451)
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Solid Tumors, Gastric Cancer
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.
- Conditions
- Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer
- Trial name
- NCT06783569
- Testing
- JR8603
- Where
- 2 sites in China
- Volunteers
- 94 people
- Sponsor
- JiaRay Group
Locally Advanced or Metastatic Epithelial Tumor
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of…
- Trial name
- NCT04603287
- Testing
- SI-B001
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Rectal Carcinoma
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting
The purpose of this study is to assess the safety and efficacy of S-1 and oxaliplatin combined with radiation by Phase I/II study.
- Trial name
- NCT01227239
- Testing
- S-1, Oxaliplatin, Radiation
- Where
- 6 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Japan Clinical Cancer Research Organization
Rectal Cancer, Locally Advanced Malignant Neoplasm
Microbiome and Rectal Cancer
The purpose of our study is to determine if an association exists between the microbiome of those with rectal adenocarcinoma who are complete pathologic responders and those who have a partial or no response to neoadjuvant…
- Trial name
- NCT04223102
- Testing
- Tissue collection
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of South Florida
CRC (Colorectal Cancer)
Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
The goal of this clinical trial is to learn if SHR-1701 combine with chemoradiotherapy works to treat severe CRC. Participants will take: Induction: SHR-1701 combined with CAPOX for one cycle.
- Trial name
- MA-CRC-II-018 (NCT07478731)
- Testing
- SHR-1701 neoadjuvant
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hong Qiu
Rectal Cancer
Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer
Concurrent chemoradiotherapy (CRT) Radiotherapy 25 ㏉/5 fractions (start concomitantly at D1) ↓ ↓ ↓ ↓ ↓ Radical surgery 6 weeks after completion of chemoradiotherapy ↑ ↑ ↑ ↑ ↑ D1 - - - - - D5 5-Fluorouracil 400㎎/㎡/day + LV…
- Trial name
- NCT01129700
- Testing
- Radiation: short-course preoperative chemoradiotherapy
- Where
- South Korea
- Volunteers
- 73 people
- Sponsor
- National Cancer Center, Korea
Rectal Cancer
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
The concurrent neoadjuvant chemoradiation therapy is standard care for local advanced rectal cancer (LARC), however, this regimen may induce sorts of adverse events, and part of them even more severer.
- Trial name
- NCT02942563
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Rectal Carcinoma
Resource-Sparing Curative Treatment for Rectal Cancer
This is a prospective, multicentre, randomized clinical trial comparing two different neo-adjuvant radiation-based strategies prior to intended surgery for locally advanced adenocarcinoma of the rectum.
- Trial name
- NCT01459328
- Testing
- Radiotherapy
- Where
- 12 sites in Algeria, Brazil and 9 more
- Volunteers
- 350 people
- Sponsor
- International Atomic Energy Agency
Rectal Cancer
Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer.
Metformin is an oral antidiabetic of the biguanide class derived from galega officinalis. Historical cohort of patients with diabetes have shown that diabetics on Metformin had a better chance of survival than diabetics not on…
- Trial name
- METCAP (NCT02437656)
- Testing
- Metformin
- Where
- 11 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Oscar Lambret
Metastatic Colorectal Cancer, Gastric Cancer
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
This is an open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of vactosertib in combination with pembrolizumab in patients with metastatic or locally advanced colorectal or…
- Conditions
- Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03724851
- Testing
- TEW-7197
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- MedPacto, Inc.